INTRODUCTION
Despite revolutionary changes in the field of medicine and eradication or prevention of many diseases worldwide in the past few decades, rheumatic heart disease (RHD) still remains as one of the largest preventable disease burdens in the world and is seen to be more prevalent in the developing countries 1 .
Majority of RHD patients develop valvular heart disease with mitral valve incompetence as the most common valvular lesion seen in these patients 2 . In symptomatic patients or those in whom evidence of impaired LV function at rest is seen, surgical intervention is the definitive treatment 3 .
Patients who undergo surgical intervention may have either a bio prosthetic valve replacement or a mechanical valve replacement. Those in the latter group requires to be initiated on vitamin K receptor antagonist drugs like warfarin in order to prevent thrombus formation of the mechanical valves.
Since its discovery in 1940 4 , warfarin has withstood the test of time despite many newer oral anticoagulants in the current medical scenario.
In our Indian scenario, warfarin continues to be the mainstay oral anticoagulant of choice among majority of physicians 5 .
The main disadvantage is the narrow therapeutic index with patients on warfarin "walking a tight rope between bleeding and clotting" 5 . Warfarin does not require any loading doses and can be begun along with unfractionated heparin or low molecular heparin (LMH) with an overlap of 4 to 5 days to prevent rebound thrombosis from fall in protein C levels 5 . Current recommendations indicate that patient can be started on warfarin at a dose of 4mg to 5mg daily 5 . Initial check INR can be performed at least four times a week until the desired INR value is attained. Current recommendations state that once a stable therapeutic INR is achieved , follow up can be done at 1 month intervals 5 .
Certain issues exist with warfarin which are peculiar to the Indian population which results in coagulation abnormality.
Therefore this study was done in heart valve replacement patients who require lifelong warfarin treatment with an aim to understand issues related to warfarin interaction and how to minimize them.
AIM
To evaluate the determinants of bleeding in post heart valve replacement patients on warfarin therapy OBJECTIVES 1. To identify contributing factors for bleeding Manifestations or INR >4.5 in patients already on warfarin therapy following heart valve replacement.
Mechanical heart valves can be advised according to patient preference, and can be prescribed for patients who wish to avoid a second surgery which is indicated in bioprosthetic valves. On the other hand, bio prosthetic valves decrease the need for long term treatment with warfarin, but have limited durability and may require a second surgery in case of failure.
However the outcomes are similar with implantation of either a mechanical valve or bio prosthetic valve between 60 and 70 years of surgery 11 . One of the main complications of mechanical prosthetic valve is thrombosis. It is seen that the prevalence of thrombosis of mechanical heart valve is only 0.3-1.3% per patient-year in developed countries, as compared to 6.1% per patient -years seen in developing countries 11 . Therefore mechanical heart valve replacements requires proper understanding about the coagulation cascade, mechanism of action of warfarin and factor influencing its metabolism.
BLOOD COAGULATION
Hemostasis is the process of blood clot formation at the site of vessel injury. Haemostasis and blood coagulation involve complex interactions between injured vessel wall, coagulation factors and platelets . The process of clot formation requires a well regulated relationship between the pathways of thrombin stimulated fibrin clot formation and plasmin induced clot lysis which when works effectively leads to clot formation initially and later by lysis of clot and tissue remodeling. The factors for abnormal bleeding may be due to diminished thrombin generation (e.g. due to factor VIII deficiency) or increased clot lysis (e.g. due to alpha 2 antiplasmin deficiency). The coagulation process that generates thrombin consists of two interrelated pathwaysextrinsic and intrinsic systems.
The extrinsic system is initiated by the activation of the clotting Factor VII. The intrinsic system is initiated by activation of clotting Factor XII, following its contact in vitro by glass. Both intrinsic and extrinsic systems involve a cascade of enzymatic reactions which leads to transformation of various plasma factors (proenzymes) to their active (enzymatic) enzymes leading to thrombin production. This coagulation cascade forms the basis of oral anticoagulants
NEWER ANTICOAGULANTS IN THE HORIZON:-
Direct thrombin inhibitors :-As the name suggests, these group of anticoagulants act directly with the thrombin and inhibit the activity of thrombin bound to fibrin as well as well as soluble thrombin which leads to limitation of thrombus progression 12 . Dabigatran etexilate belongs to this group and has been approved for prevention of stroke in atrial fibrillation. It is currently marketed in India. Dabigatran has a low bioavailability of 6% and its activation is not mediated by cytochrome P450 enzymes. It has a half life of 12-24 hrs and is excreted mainly by renal. Many serious side effects have been reported with the use of dabigatran. It also has drugdrug interactions. When used with drugs like rifampicin, the therapeutic effect is decreased whereas co administration with NSAIDs, clopidogrel leads to increased risk of bleeding 13 .
Factor Xa inhibitors
Rivaroxabane is a direct competitive inhibitor of factor Xa . The metabolism is by CYP3A4, CYP2J2 and other mechanisms which lead to variety of drug interactions. It is therefore contraindicated with anti-HIV protease inhibitors and azole group of drugs and in renal failure patients. Rivaroxabane is bound extensively to plasma proteins and with a half life of 7-11 hrs and a high bioavailability (80%). The main side effects are bleeding and anemia and other associated side effects are tachycardia , pruritis, elevated liver enzymes , hypotension and nausea.
Another direct selective inhibitor of factor Xa is apixaban. It has > 30,000 fold selectivity over other coagulation proteases. Currently Apixaban is undergoing various clinical trials for thrombo-prophylaxis in knee and hip replacement and prevention of stroke in atrial fibrillation. It has a half life of 8-15 hours when given orally and can be given once or twice daily. Its metabolism is through O-demethylation. It reacts with drugs that induce or inhibits CYP3A4.
Edoxaban, betrixaban , TAK442 and YM150 are other factor Xa inhibitors currently undergoing development. Despite these newer drugs and availability of dabigatran in the Indian market, warfarin still continues to be the leading oral anticoagulant used in our Indian population due to physician comfort and prohibitive cost of dabigatran.
"Advantages and Disadvantages of Newer Anticoagulants 5 ,
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Advantages
• Rapid onset of action, so no need for bridging therapy
• Short half-life, so easy control of anticoagulant effect
• Little or no food interaction, so no dietary restrictions like warfarin
• Limited drug interactions unlike warfarin
• Predictability of anticoagulation effect without a need for routine coagulation monitoring.
Disadvantages
• Prohibitively high cost resulting in poor compliance 17 .
WARFARIN MECHANISIM OF ACTION
Warfarin is a coumarin derivative which produces anticoagulant effect by interfering with cyclic inter conversion of Vitamin K and its 2, 3 epoxide. Vitamin K plays an important role as a cofactor in the carboxylation of glutamate residue to carboxyglutamates on the N-terminal regions of vitamin K dependent proteins. Vitamin K is required for the -carboxylation of coagulation factors II,VII,IX and X. Warfarin by inhibiting vitamin K conversion cycle, induces hepatic production of partially decarboxylated proteins with reduced coagulant activity 18 . The binding of vitamin K dependent coagulation factor to phospholipid surfaces is regulated by carboxylation which leads to acceleration of blood coagulation.  -Carboxylation essentially requires the reduced form of vitamin K (vitamin KH2) 19 . By blocking vitamin KH2 formation , coumarins inhibit the enzyme vitamin K epoxide reductase which in turn leads to limiting of the  -carboxylation of vitamin K dependent coagulant proteins.
Vitamin K anatagonists also inhibits carboxylation of the regulatory anticoagulant protein C and S and therefore exert procoagulant response. Low doses of vitamin K 1 (phytonadione) helps to overcome the effect of coumarins by bypassing vitamin K epoxide reductase. Warfarin also interferes with the carboxylation of Gla proteins synthesized in bone 20 21 22 . Due to these reasons, warfarin is thought to contribute to fetal bone abnormalities especially when mothers are treated with warfarin at the time of pregnancy. However there is no clear cut evidence suggesting direct relationship of warfarin and bone metabolism when administered to children or adults.
WARFARIN
PHARMACOKINETIC AND PHARMACODYNAMICS
Warfarin is a racemic mixture of 2 optically active isomers, the R and S forms 23 . In which potency of S-warfarin is approximately 5 times more than that of R-warfarin. Cytochrome P450 (CYP) 2C9 enzyme is responsible for the metabolism of S-warfarin while metabolism of R-warfarin occurs through CYP3A4 & CYP1A2 24 .
It has a high bioavailability owing to the fact of rapid absorption from the gastrointestinal tract and is found to reach maximum blood concentration within 90 minutes after oral administration. The half life of warfarin is 36-42 hours and it is transported in the body to the liver bound to albumin , where the 2 isomers by different pathways are metabolically transformed 25 . It is due to this long half life that even after starting warfarin , heparin or LMW heparin is continued as part of "bridging therapy".
WARFARIN AND INR MONITORING
Warfarin has been for decades the drug of choice among the oral anticoagulants . After mechanical prosthesis, the standard of care lies in lifelong oral anticoagulation therapy. There is a reduction of nearly 75% of major embolic strokes when patients were treated with warfarin rather than isolated anti platelet therapy or no anticoagulation at all. The INR was developed by the World Health Organization"s expert committee on Biologic Standardization in the year 1982. This was done " in response to variations in thromboplastin sensitivity and different ways of reporting prothrombin time across the world" 26 27 . Previous recommendations suggest patients with mechanical valve replacement to have a therapeutic range of INR between 2.5 to 4.5. However this large range may be associated with risk for increased bleeding especially beginning from INR 3.5 . The goal of oral anticoagulation therapy post aortic valve replacement is to achieve an INR of 2.5 to 3.5 in the initial 3 months after surgery and later followed by 2.0 to 3.0 28, 29 . 31 .
WARFARIN IN PREGNANCY
Major controversy about oral anticoagulants lie in the topic related to pregnancy. Pregnancy itself with mechanical valve has a high probability of maternal complication due to alterations in hemostasis and coagulability leading to increased risk of thromboembolic events 32 2. Adjusted-dose subcutaneous LMWH therapy throughout the pregnancy in doses adjusted according to weight to achieve the manufacturer"s recommended anti-Xa level 4 hours after subcutaneous injection.
3. Unfractionated heparin or LMWH therapy (as above) until the 13th week, a change to warfarin until the middle of the third trimester, and then restarting UFH or LMWH until delivery. 5, 35 "
During postpartum period, regardless of which regimen is used, long term anticoagulation should be resumed. Heparin can be restarted, 6 hours post-vaginal birth and 12 hours post cesarean, if there is no significant bleeding.
FACTORS AFFECTING WARFARIN DOSAGE
The number of dispensed outpatient prescriptions for warfarin in the year 2004 was nearly 31 million 36 . There are various factors which affect the relationship between warfarin dosage and the required biological responses. These include environmental and genetic factors and also includes mutations in the cytochrome P450 coding gene which is responsible for the oxidative metabolism of warfarin S-isomer. Because of these various factors, maintaining appropriate level of anticoagulation in patients on warfarin treatment is complex and always requires constant INR monitoring and adjustment of dosages. Patient noncompliance, miscommunication between the patient and physician and inaccuracies in laboratory testing also leads to variability in anticoagulant response. Pharmacokinetic and pharmacodynamics are the two categories into which warfarin drug interactions can be categorized. Pharmacokinetics as the name suggests are those that are involved with metabolism of warfarin and result in change in International Normalized Ratio (INR) whereas "synergistic" or additive effect form the basis for pharmacodynamic interactions.
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DETERMINANTS OF WARFARIN INTERACTIONS
ANTI INFECTIVE AGENTS
The most common cause of warfarin interaction clinically encountered is that between antimicrobial agents and warfarin which leads to fluctuation in INR values. The various mechanisms attributed to this interactions include interference with warfarin clearance , dietary changes of patients on antibiotic therapy resulting in reduction of vitamin K intake, imbalance of bacterial flora in the intestine leading to decreased amount of vitamin K production by intestinal bacteria. . In a retrospective evaluation, Gabriel et al 50 showed that patients concomitantly treated with warfarin and levofloxacin had a significant increase in INR values (P=0.001) which was comparable to the result found in our study.
Shrader et al 51 had published a case report in which their patient developed prolonged prothrombin time following treatment with azithromycin 500mg which later normalized after discontinuation of azithromycin. The possible explanations may be due to interaction occurring as a result of either "infection induced changes in gastrointestinal flora, the inhibition of warfarin metabolism by the CYP450 system, and competitive protein binding." Likewise Foster et al 52 Among the different classes of anti retrovirals, non nucleotide reverse-transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) accounts for majority of interactions with warfarin as they are both metabolized by multiple CYP450 enzymes. Stefano Bonora et al 57 in their case report had documented INR elevation from 2.7 to 7.0 and gross haematuria in a patient with history of co administration of warfarin and efavirenz for a total duration of 3 weeks. 
ANTI -INFECTIVE CARDIOVASCULAR DRUGS
ANALGESICS
ANTIHYPERLIPIDEMIC AGENTS
In the current medical practice, the use of anti hyperlipidemic agents have increased dramatically due to its ability to decrease the risk of coronary events and stroke. Statistics have showed that approximately 30% of patients taking warfarin also take antihyperlipidemic agents. Schelleman et al 64 in an observational case control study by using Medicaid claims data , evaluated the risk of gastro intestinal (GI) bleeding in patients on warfarin after commencing statin or fibrate. Their results showed that chronic warfarin users had an increased odds ratio of GI bleeding upon starting of gemfibozil ( 1.88; 95% CI,1.00-3.54), simvastatin (1.46; 95% CI 1.03-2.07), atorvastatin (1.39; 95% CI 1.07-1.81). There was no increased risk seen with pravastatin (0.75; 95% CI,0.39-1.46). The reason may be attributed to the fact that simvastatin and atorvastatin are predominantly metabolized by CYP3A4 whereas pravastatin and rosuvastatin utilize CYP3A4 to a much lesser extend. Therefore if the need for statin therapy arises, physicians should judiously prescribe an agent with fewer documented interactions.
NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) / SELECTIVE CYCLOOXYGENASE (COX)-2 INHIBITORS
NSAIDs ever since its discovery, is the most widely used drugs worldwide to control inflammation or musculoskeletal pain . NSAIDs apart from their antiplatelet function, by direct interactions can affect pharmacological action of warfarin. In a recent retrospective case control study using tertiary hospital medical records of 98 patients, Choi et al 65 Similarly the risk of hospitalization for upper GI bleeding is increased in elderly patients when they took selective COX-2 inhibitors along with warfarin. A nested case-control analysis of multiple linked health care databases showed that out of 98821 elderly patients aged 66 years or more continuously receiving warfarin, 361 (0.3%) were admitted with upper GI hemorrhage 66 . The results after adjusting for potential confounders signify that case patients were more likely to be taking nonselective NSAIDS (OR, 1.9; 95% CI, 1.4-3.7), celecoxib (OR, 1.7; 95% CI, 1.2-3.6), or rofecoxib (OR, 2.4; 95% CI, 1.7-3.6) prior to hospitalization. As COX-2 inhibitors have rapidly gained acceptance in both Indian and Western clinical practice and accounts for fastest growing prescription medicine , care must be given by physicians and pharmacists when prescribing them to elderly patients on warfarin treatment due to possible interactions between both groups.
INTERACTION WITH ISONIAZID AND RIFAMPICIN
Isoniazid and rifampicin are the mainstay drugs used in the treatment of pulmonary and extrapulmonary tuberculosis. Rosenthal et al 67 in their case report record a 35 year old man admitted with coagulation abnormality after taking double dosage of isoniazid. Similarly by increasing the rate of warfarin clearance, rifampicin lowers plasma warfarin concentration. This could probably be due to a differential effect of warfarin stereoisomer metabolism or due to an altered dynamic effect 68 .
GENETIC FACTORS
In the last decade, several studies were done in the area of warfarin dosage to genetic variants in genes involved in warfarin activity and metabolism and has shown consistent association with polymorphism in CYP2C9and VKORC1 gene variant. Direct association between warfarin dosage and CYP2C9 gene variant was first reported by Aithal and associates in the year 1999 69 , whereas study on VKORC1
gene variant on warfarin doses were published in 2004 70 .
CYP2C9*2 (430C>T) and CYP2C9*3(1075A>C) are the two most reported and studied polymorphism in CYP2C9 gene. Among this *2 allele has impaired hydroxylation of Swarfarin with 12% while *3 allele has less than 5% of wild type activity. As the result of these variations, there is a decrease in the degradation and warfarin clearance due to which a low dosage of warfarin is required to maintain therapeutic INR 71 .
Another important factor affecting warfarin dosage is the promoter polymorphism VKORC1-1639G>A which is present withVKORC11173C>T. The binding site for VKORC1 transcription is altered and as a result of which there is lower VKORC1 mRNA expression in human liver. As the result of this , patients are more susceptible to inhibition by warfarin causing warfarin sensitivity 71, 72 . Previously published articles 73-75 have showed that in Indians, presence of VKORC1 variant allele is 12-14% of the population. Natarajan.S et al. 76 in their study state that individuals were found to be sensitive to warfarin therapy even if there was presence of a single copy of variant allele. 79 80 , UK medicines and health care products Regulatory Agency (MHRA)/Committee in Safety of Medicines (CSM) advised patients taking warfarin to avoid cranberry juice or products. In the wake of this precautionary statement issued by the FDA, many other larger studies were published which showed no significant interactions. Ansell et al. in their study of 30 patients on stable warfarin doses performed randomization and the patients received 240 ml of cranberry juice daily for 2 weeks 81 . At the end of the study there was no significant change in INR from the baseline. Another recent study prospective open labeled study 82 was conducted where 10 patients receiving warfarin was given 240ml of cranberry juice twice daily for 1 week. There was no significant changes noted in the INR values and there was no adverse events and no reported bleeding or bruising.
B. GREEN TEA:-Also known as Chinese tea is one among the most widely consumed beverages world wide.
Various myths related to treatment of gastrointestinal disorders, enhancement of cognition and prevention of various cancers help to promote green tea consumption. The topic of concern is whether green tea contains vitamin K or not. James Taylor 83 had reported a case of 44 year old male who was on warfarin treatment for stroke prevention after receiving St Jude"s mechanical heart valve presenting with significant decrease in INR value after patient consumed green tea. Patients previous records showed an INR of 3.2 while patient was on warfarin 7.5mg. following drinking one half to one gallon of green tea daily for 1 week, patient"s INR dropped to 1.3 which returned to 2.5 after discontinuation of tea consumption. By using reverse-phase, vitamin K content of green teas was analyzed in an observational study 84 which revealed that dried green leaves contained 482mcg/100g of vitamin K and boiled green leaves contained 433 mcg/100g compared to only 0.03mcg/100g of vitamin K in brewed tea. Therefore significant interaction with warfarin is unlikely to happen with occasional consumption of brewed green tea. C. GREEN LEAFY VEGETABLES: -As mentioned earlier, there are many drugs which can affect warfarin anticoagulation. To avoid dietary vitamin K-warfarin interactions, patients on warfarin therapy are advised to consume a constant dietary intake of vitamin K. The best sources of vitamin K are leafy vegetables which provide 50-800 plg vitamin K/100g 85 . Consumption of green leafy vegetables inconsistently is often the main cause of vitamin K fluctuation status 86 . As the result of which patients may present with evidences of anticoagulation and may receive increased doses of warfarin which may ultimately lead to over anticoagulation. D. FENUGREEK:-It is one of the oldest medicinal plants originating in India where it is used mainly as a condiment 87 . "It also contains alkaloids including trigonelle, gentian, and carpaine, as well as proteins rich in lysine, nucleoproteins rich in iron and phosphate, lecithin, steroids, coumarin glucosides, carbohydrates, mucilage, lipids, and saponins capable of hemolysis in aqueous solution." 88, 89 Fenugreek has many properties when taken orally. This includes lowering blood sugars in diabetics, stimulating appetite, reducing high cholesterol and triglyceride levels. The exact mechanism of its interaction with warfarin is unclear .However many case reports have been reported concomitant use of warfarin with fenugreek resulting in increase in INR values and by stopping the use, warfarin was seen to normalize 75 .
NON COMPLIANCE:-
One of the major factors found to attribute towards warfarin induced coagulation abnormality is the factor of non compliance to drug therapy especially in elderly patients. The different ways in which this can be manifested includes getting a prescription filled but failing to take the drug, failing to have a prescription filled, not following the dose or frequency of drug prescribed. Warfarin is a "double edged sword" which requires good compliance with medication dose and prothrombin testing for optimal benefit or else may lead to coagulation abnormalities . 
MATERIALS AND METHODS
This was a prospective unmatched case control study . There were 50 patients recruited as case and an equal number of controls. The two groups had participants who had underwent post heart valve replacement and was on treatment with warfarin at the time of study. The first group recruited patients whose INR values were more than 4.5 and were termed as cases. The second group consisted of patients whose INR values were less than 4.5 and were termed as controls. Individual groups had appropriate tests done as detailed below. The data was then analyzed and association determined. Patients aged less than 14 or more than 80 years , on warfarin therapy for morbidities like atrial fibrillation, deep vein thrombosis prophylaxis were excluded in this study.
Details of Study
Parameters Studied:
The factors contributing or leading to coagulation abnormalities or INR more than 4.5 in post heart valve replacement patients receiving warfarin therapy in terms of:
Concurrent usage of antibiotics and other drugs:-This was done with the help of structured questionnaire. History of antibiotic/ NSAID use within past 1 week was taken into account which was verified by either outside prescription, medication cover or by telephonic confirmation with relatives of patients who were unsure of medication.
Compliance versus Non compliance:
Patients were categorized as compliant and non compliant based on structured questionnaire which included last documented follow-up, last documented INR , dietary adherence in the past two months, documented versus actual warfarin dose that patient was taking and any history of double dosing of warfarin INR monitoring:-This was done only at the time of study based on which patients were categorized as cases or controls. Liver function tests and platelet counts were also done to rule out other medical causes which could precipitate bleeding manifestations Educational factors:-This was assessed based on Kuppuswamy"s socioeconomic scale.
Dietary Factor :-This was done based on structured questionnaire of diet intake since past two months with regard to green leafy vegetables ( e.g spinach, cabbage, Broccoli, green leafy lettuce) prior to last documented INR and prescribed warfarin dose. Patients were also asked about the intake of green tea and cranberry juice after the last documented INR and prescribed warfarin dose.
Distance to hospital Factor:-This was done by questionnaire and by plotting the distance with reference to map.
Brief Procedure:
Patients who attended PIMS hospital on OPD basis or patients who are admitted with INR more than 4.5 or with bleeding manifestations and currently on warfarin therapy were assessed in this study and were taken as the cases. Another group of unmatched patients who also underwent heart valve replacement and with INR values less than 4.5 were taken as controls. Patients were clearly explained about the study that is being done and was reassured about the maintenance of confidentiality . Questionnaires were handed out to the patients after obtaining their consent in the consent form. Patient"s liver function test and INR test routinely done was noted for study purpose. Following participation in the study, patients were advised about how to prevent warfarin-induced coagulation in future.
Method of statistical analysis:
1. Number and percentage was used to describe characteristics of subjects. 2. Chi square test was used to assess the association.
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3. Odds ratio , confidence interval and P value were used to assess risk in case control study. Odds ratio of > 1.0 was considered as risk and <1.0 was considered as protective effect.
4. Multivariate analysis to assess independent association of relevant variables found significant in the univariate analysis (less than 20% level).
5. P value <0.05 was considered as statistically significant
Ethical Considerations
1. Informed Consent was taken after clearing explaining to the participants about the study being done. As these patients were on lifelong oral anticoagulants any factors that could influence the outcome was of utmost importance to reduce the morbidity and mortality in this group. 2. Confidentiality of the information obtained from the patients as well as the biochemical parameters was maintained in both groups of patients.
3. The benefits of doing this study was duly informed to the study participants . All the patients were advised on how to improve the compliance to the treatment and maintain the INR values. 4. The participants were recruited in the study irrespective of the gender or socioeconomic status 5. Participants were not exposed to any increased risk as a result of the study and those participants who needed further management were subjected to the same. 6. No therapeutic intervention was done 7. The ethical approval was obtained from the P.I.M.S Institute Ethics Committee prior to the study .
RESULTS
There was a total of 100 participants who had underwent post heart valve replacement and currently on warfarin therapy. The first group consisted of 50 patients whose INR values were more than 4.5 or those with evidence of bleeding manifestations and therefore they were classified as cases. The second group also consisted of 50 patients whose INR values were less than 4.5 and were classified as controls. Both cases and controls were unmatched.  Similarly in terms of educational status, case group had 34 participants who had completed below high school as compared to 24 participants who had passed high school seen in the control group.  These results were not statistically significant stating that there is no difference between the cases and controls. Participants who were taking NSAIDs were 4.57 times increased risk of having INR more than 4.5 when compared with participants not taking NSAIDs. (CI : 0.91 -22.7). The result was not statistically significant. Participants who were taking Antibiotics were 2.52 times at increased risk of having INR more than 4.5 when compared with participants not taking Antibiotics. (CI : 0.72 -8.81). The result was not statistically significant. Participants who were non compliant to medication were having an increased chance of having INR above 4.5 when compared with participants who are compliant to treatment.(OR : 4.33 CI : 1.78 -10.52 ). The results were statistically significant. Among the 100 participants in the study , 36 % were found to be non compliant with treatment as compared to 64% who were compliant . Among the latter group, 40 patients (62.5%) belonged to the control group and only 24 (37.5%) belonged to the case group Fisher Exact =1.00 Table 7 Fisher exact =<0.001 Chi square = 0.0857
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Educational status among 100 participants showed that 13 patients (68.4%) who were illiterate belonged to the compliance group whereas 11 patients (40.7%) in the non compliance group had completed high school. The results were found to be statistically insignificant (P=0.0857). 
DISCUSSION
Warfarin is a "double edged sword" , when used in its optimal range it can be beneficial for patients. But any deviation towards either extremes can lead to serious morbidity and even mortality. More than 2 million Indians take warfarin and it is more prescribed in the elderly population based on physician comfort due to years of usage 5 .
The purpose of this study was to identify contributing factors for bleeding Manifestations or INR >4.5 in patients already on warfarin therapy and to address factors which increase patient compliance.
As there is a narrow therapeutic index existing among oral anticoagulants, therapeutic control is often difficult 92 . This makes compliance to treatment very crucial. Therefore the initial parameter that we studied was the level of non compliance. In our study, 36% of study participants among both cases and controls were found to be non compliant with the treatment as compared to 64% who were compliant. Among the latter group, 40 patients (62.5%) belonged to the control group and only 24 (37.5%) belonged to the case group which was statistically significant [ OR= 0.23( 95% CI=0.09-0.56), P=0.002].
In terms of finding the contributing factors, certain key issues related to warfarin had to be considered. To begin with our Indian population vary a lot when compared to the western population in certain issues with warfarin. One of the major factor that played a pivotal role in warfarin interaction was the dietary habits which differed from that of the west. Kakkar et al 92 conducted a study based on the review of case records of 82 patients who were on anticoagulant therapy for a minimum duration of three months. Their study revealed that among outpatient , the overall therapeutic control was generally poor leading to a state of under anticoagulation of patients for most period of treatment. The rate of complication was also unacceptably high. This could be attributed to the fact that there is a lack of proper laboratories with standardized measurement of prothrombin time even in suburbs of large cities.
In the long run for optimal management of INR, not just the patients, but even physicians also have a large role to play in the general outcome of patients. Maintenance of optimal INR requires dosage regulation, frequent laboratory testing, , prompt diagnosis and treatment of thromboembolic or hemorrhagic complications in addition to compliance factor and patient education. Kakkar et al. 93 conducted over a 16 Among area which needs to be addressed is the area of taking wrong dosage/ self medications. In our study out of 36 non compliant patients, 9 patients (25%) gave history of taking wrong dosage of warfarin. This could be attributed to the practice of taking double medicines in case of prior missing of regular dose. Wrong interpretation of dose prescribed could also lead to this.
Another parameter which we found significant in our study was the relation of educational status among the study subjects. Our study on educational status in concordance with Kuppasamy"s scoring chart revealed that 63.2% of illiterate subjects belonged to the case group whereas 59.3% of subjects who had passed high school were seen in the control group (P=0.05) . This shows that literacy places a conclusive role as determinant in warfarin resistance.
Other contributing factors noted in our study is over anticoagulation. These were 3 such patients who had presented with h/o of struck valve and therefore their warfarin dosages were increased as a result of which , these patients developed iatrogenic induced coagulation abnormality. Similarly we had 1 patient who was a known case of coronary artery disease and chronic liver disease as a result of which had elevated INR values. Our study also had 3 patients for whom no reasons could be found for coagulation abnormality and hence were classified as with unknown causes.
Not all patients presenting with coagulation abnormality had bleeding manifestations. Among the 50 study populations enrolled as cases, only 17 patients (34%) had bleeding manifestations. Majority of patients (20%) presented with gum bleeding followed by hematoma (10%). There was 1 case each who presented with haemoptysis and per vaginal bleeding.
Our study had its drawbacks. First of all it was an unmatched case control trial. The possibility of whether genetic factors and phenotypes played a role in our study was not assessed .The study may have shown significant association in terms of age, gender and distance if the sample size in each group were more. Similarly the duration since valve replacement was not taken into account. 
SUMMARY
CONCLUSION
Non compliance to medication was found to be a risk factor for increased INR and was statistically significant. Gender, age, educational status, intake of NSAIDs and antibiotics were found to be a risk factor which increased INR but it was not statistically significant. Wrong dosage, intake of green leafy vegetables and delay in follow up were found to be risk factor for non compliance but it was not statistically significant.
